Exploratory pilot study of exogenous sustained‐release melatonin on nocturia in Parkinson's disease

Abstract

In this preliminary open-label study, administration of sustained-release melatonin 2 mg was found to be safe for clinical use and was associated with significant improvements in night-time frequency and nocturnal voided volumes in PD patients.